Liquidia Technologies is projected to report Q3 2026 revenue of $214.18 million and an EPS of $0.77, with the current stock price of $45.88 trading significantly below the average analyst target of $59.00. The primary focus for investors is the massive October 2026 global settlement with United Therapeutics, which successfully resolved all pending litigation and secured long-term market access for Yutrepia.
While the agreement removes injunction risks, it requires Liquidia to pay $380.7 million in installments and discontinue the PH-ILD indication from its label. Market participants are also scrutinizing preliminary Yutrepia net product sales of $222.7 million for evidence that sustained adoption in the PAH segment can offset these settlement costs.